No Data
No Data
Announcement of Dali Pharmaceutical Co., Ltd.'s anticipated half-year performance loss for 2024.
ST Daphar (603963.SH) is expected to lose 11-14 million yuan in the first half of the year.
On July 12th, Gelunhui reported that *ST Deyaoyao (603963.SH) announced a pre-loss notice for its 2024 interim performance. According to preliminary calculations by the financial department, the net income attributable to the owner of the parent company for the first half of 2024 is expected to be between -14 million yuan and -11 million yuan, and compared with the same period of the previous year (legally disclosed data), the loss will increase from 3.2176 million yuan to 0.2176 million yuan. It is expected that the net income attributable to the owner of the parent company after deducting non-recurring gains and losses in the first half of 2024 will be -16 million yuan to -13 million yuan.
*Special Treat Da Yao (603963.SH): Currently has no medicinal plant cultivation base.
On July 10th, Gelunhui reported that ST Deyao (603963.SH) stated on the investor interaction platform that the company currently does not have any medicinal herb planting bases.
*ST Pharmaceutical (603963.SH): As of April 19, 2024, the number of shareholders of the company was 33,375
Gelonghui, April 30丨*ST Pharmaceutical (603963.SH) said on an interactive platform that as of April 19, 2024, the number of shareholders of the company was 33,375.
Dali Pharmaceutical (603963.SH) announced 2023 annual results with a net loss of 2003 million yuan
According to the Zhitong Finance App, Dali Pharmaceutical (603963.SH) disclosed its 2023 annual report. The company achieved revenue of 87.27 million yuan during the reporting period, a year-on-year decrease of 34.06%. The net loss attributable to shareholders of the listed company was RMB 200314 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 25.22,900.
Dali Pharmaceutical (603963.SH): Shenmai injections were not selected for procurement by the Hubei Provincial Federation of Proprietary Chinese Medicine
Zhitong Finance App News, Dali Pharmaceutical (603963.SH) issued a stock price change announcement stating that the company's Shenmai injections were not selected for procurement by the Hubei Provincial Federation of Proprietary Chinese Medicine, and that the sales volume of Shenmai injections in the original grade hospital market was basically lost. The company's Shengnaojing injections were selected by the Guangdong Six Provincial Proprietary Chinese Medicine Alliance, and sales of Xingnaojing injections will drop by a large percentage in the six allied provinces. The company has selected the National Proprietary Chinese Medicine Procurement Alliance for centralized volume procurement. Although sales are gradually picking up, gross profit has declined due to a sharp drop in sales prices.
No Data